We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


  Gold Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
27 Oct 2021 - 29 Oct 2021

Fecal Calprotectin Predicts Therapy Outcome in Ulcerative Colitis Patients

By LabMedica International staff writers
Posted on 24 Aug 2021
Print article
Image: Schematic representation of calprotectin indications in clinical practices and main advantages (Photo courtesy of Hôpital Beaujon)
Image: Schematic representation of calprotectin indications in clinical practices and main advantages (Photo courtesy of Hôpital Beaujon)
Ulcerative colitis (UC) is a chronic intestinal disorder of unknown etiology and characterized by a relapsing and remitting course. The diagnosis and assessment of the disease activity has been based on clinical symptoms, laboratory measurements, findings of endoscopy and pathological examinations.

The development of a non-invasive and simple biomarker for evaluating the disease activity is considered necessary for the clinical management of UC. Calprotectin is a complex of mammalian proteins found in the cytosol of human neutrophils, monocytes and macrophages. Granulocyte and monocyte adsorptive apheresis (GMA) is widely used as a remission induction therapy for active UC patients.

A large team of Gastroenterologists at the (Asahikawa Medical University, Asahikawa, Japan) and their colleagues conducted a multicenter prospective observation study of patients who received 10 sessions of GMA, twice a week, for five consecutive weeks. A total 36 patients with active UC were enrolled in the study. Fecal calprotectin was measured at entry, one week, two weeks, at the end of GMA and on the day of endoscopy within 24 weeks after GMA.

The patients’ stool samples were homogenized by mixing with a predefined extraction buffer volume. After centrifugation, the supernatants were subjected to a fluorescence enzyme immunoassay using EliA Calprotectin 2 (Thermo Fisher Scientific, Tokyo, Japan). Laboratory values, including the white blood cell (WBC) count and C- reactive protein (CRP) level were also measured at the same time points as FC measurement: at entry, one and two weeks and at the end of GMA and on the day when endoscopy was performed within 24 weeks after GMA. The team analyzed the relationships between the clinical outcome (clinical remission [CR] and endoscopic remission [ER]) and the change in FC concentration.

The investigators reported that the overall CR and ER rates were 50.0% and 19.2%, respectively. After GMA, the median FC concentration in patients with ER was significantly lower than that in patients without ER (469 mg/kg versus 3,107 mg/kg). When the cut-off value of FC concentration was set at 1,150 mg/kg for assessing ER after GMA, the sensitivity and specificity were 0.8 and 0.81, respectively. The FC concentration had significantly decreased by one week. An ROC analysis demonstrated that the reduction rate of FC (ΔFC) at one week was the most accurate predictor of CR at the end of GMA (AUC = 0.852). When the cut-off value of ΔFC was set at ≤ 40% at one week for predicting CR at the end of GMA, the sensitivity and specificity were 76.9% and 84.6%, respectively.

The authors concluded that they had evaluated the utility of FC as a biomarker for assessing ER after GMA and predicting CR in the early phase during GMA in patients with active UC. The findings will benefit patients with active UC by allowing them to avoid unnecessary invasive procedures and will help establish new strategies for GMA. The study was published on August 6, 2021 in the journal BMC Gastroenterology.

Related Links:
Asahikawa Medical University
Thermo Fisher Scientific

Gold Supplier
SARS-CoV-2 Multiplex Real-Time RT-PCR Assay
GSD NovaPrime Plus SARS-CoV-2
Molecular Diagnostic Platform
Bulk Sorter
Gold Supplier
Fully Automated Batch Immunoanalyzer

Print article



view channel
Image: Psoriatic plaques, showing a silvery center surrounded by a reddened border (Photo courtesy of Jane Bianchi, BA)

Hematological Parameters Compared in Psoriasis Patients

Psoriasis is a chronic, immune-mediated disorder that can involve the skin and/or joints. Four clinical types of psoriasis are currently recognized: psoriasis vulgaris (PsV), pustular psoriasis (PP), erythrodermic... Read more


view channel

Sysmex Inostics Launches New Ultra-Sensitive Leukemia Blood Test for Early Detection of Cancer Cells Following Initial Therapy

Sysmex Inostics (Baltimore, MD, USA) has developed a new CLIA-validated liquid biopsy test for the detection of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML) to better help in the fight... Read more


view channel
Image: QIAreach QuantiFERON-TB (Photo courtesy of QIAGEN N.V.)

Qiagen Launches Novel Tuberculosis Blood Test That Marks Quantum Leap from Traditional TB Skin Test

QIAGEN N.V. (Venlo, Netherlands) has announced the launch and CE marking of QIAreach QuantiFERON-TB test for tuberculosis (TB) infection, in order to help achieve global TB elimination targets by increasing... Read more


view channel
Image: GastroPanel Quick Test (Photo courtesy of Biohit Healthcare)

Biohit’s Innovative GastroPanel Quick Test Receives CE Mark

Biohit Healthcare’s (Helsinki, Finland) GastroPanel Quick Test, the latest innovation in its unique GastroPanel product family, is now CE marked. The GastroPanel Quick Test is intended for diagnosing... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.